Kura Oncology Inc.

Company Overview

Business Model: Kura Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for the treatment of cancer. The company has transitioned from a research and development (R&D) focus to a fully-integrated commercial-stage organization. Its pipeline consists of small molecules designed to target cancer signaling pathways in oncology and hematology. Primary revenue generation mechanisms include product sales of its approved drug, KOMZIFTI, and collaboration and license agreements.

Market Position: Kura Oncology, Inc. recently achieved commercial-stage status with the FDA approval of KOMZIFTI. KOMZIFTI is the first and only menin inhibitor approved by the FDA for once-daily oral administration. The company estimates the initial U.S. market opportunity for relapsed or refractory NPM1-mutated Acute Myeloid Leukemia (AML) to be approximately $350.0 million to $400.0 million annually. The total annual U.S. market opportunity across relapsed or refractory and frontline AML is estimated at approximately $7.0 billion. The company faces intense competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies globally.

Recent Strategic Developments:

• FDA Approval of KOMZIFTI: On November 13, 2025, the FDA approved Kura Oncology, Inc.'s new drug application (NDA) for ziftomenib, marketed as KOMZIFTI, for the treatment of adults with relapsed or refractory NPM1-mutated AML who have no satisfactory alternative treatment options. Commercial sales in the United States commenced on November 21, 2025.
• Kyowa Kirin Collaboration: In November 2024, Kura Oncology, Inc. entered into a collaboration and license agreement with Kyowa Kirin Co., Ltd. and Kyowa Kirin, Inc. for the global development and commercialization of ziftomenib in AML and other hematologic malignancies. This includes a co-promotion and medical affairs agreement in the U.S. (June 2025).
• Advanced Clinical Trials for Ziftomenib:
  • Initiated KOMET-017, a single protocol comprising two global, randomized, double-blind, placebo-controlled Phase 3 trials for ziftomenib in combination with intensive and non-intensive chemotherapy in newly diagnosed NPM1-mutated or KMT2A-rearranged AML (September 2025).
  • Dosed the first patient in a KOMET-007 trial cohort evaluating ziftomenib in combination with 7+3 plus quizartinib in newly diagnosed NPM1/FLT3-ITD co-mutated AML (October 2025).
  • Dosed the first patients in the Phase 1 KOMET-015 trial evaluating ziftomenib in combination with imatinib for advanced Gastrointestinal Stromal Tumors (GIST) after imatinib failure (April 2025).
• Next-Generation Menin Inhibitor: Nominated KO-7246, a next-generation menin inhibitor, for IND-enabling studies in diabetes and cardiometabolic disorders in 2026.
• Darlifarnib Development: Initiated Phase 1b dose expansion cohorts of darlifarnib in combination with cabozantinib in advanced Renal Cell Carcinoma (RCC) (February 2026).
• Tipifarnib Trial Completion: Completed the KURRENT-HN trial evaluating tipifarnib in combination with alpelisib in Head and Neck Squamous Cell Carcinoma (HNSCC) in the third quarter of 2025.

Geographic Footprint: Kura Oncology, Inc.'s operations are primarily based in the United States, with all 260 full-time employees located domestically. The company maintains corporate headquarters and R&D facilities in San Diego, California, and additional office space in Boston, Massachusetts. Commercialization efforts for KOMZIFTI are currently focused on the U.S. market, while its collaboration with Kyowa Kirin Co., Ltd. extends ziftomenib's development and commercialization globally, with Kyowa Kirin Co., Ltd. responsible for ex-U.S. commercial strategy and sales.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 99.9%
• Operating Margin: -450.0%
• Net Margin: -413.0%

Investment in Growth (2025):

• R&D Expenditure: $251.074 million (372.1% of revenue)
• Capital Expenditures: $6.638 million
• Strategic Investments: Kura Oncology, Inc. received an upfront payment of $330.0 million from Kyowa Kirin Co., Ltd. in 2024. As of December 31, 2025, $240.0 million in development milestone payments were achieved under the Kyowa License Agreement, and $22.6 million in profit and loss sharing payments were received or expected.

Business Segment Analysis

Kura Oncology, Inc. operates in a single industry segment focused on the discovery, development, and commercialization of precision medicines for cancer. The following details are provided by key product and development programs.

KOMZIFTI (ziftomenib) - Approved Monotherapy

Financial Performance:

• Revenue: $2.132 million (2025, first commercial sales initiated November 21, 2025)
• Operating Margin: Not applicable for a single product.
• Key Growth Drivers:
  • Efficacy: KOMET-001 trial showed a 21.4% (95% CI: 14.2, 30.2) complete remission (CR) plus CR with partial hematologic recovery (CRh) rate, with a median duration of CR+CRh of five months.
  • Safety: Manageable safety profile with most adverse events (AEs) being Grade 1 or Grade 2. Includes a Black Box warning for Differentiation Syndrome (DS) with clear dose-modification guidelines, but no Black Box warning for QTc interval prolongation.
  • Compatibility: Can be co-administered without dose modification with anti-infective medications or CYP3A4 inhibitors/inducers.
  • Simplicity: First and only menin inhibitor approved by the FDA for once-daily oral administration. Product Portfolio:
• KOMZIFTI is a potent, selective, reversible, and oral small molecule menin inhibitor.
• Approved for the treatment of adults with relapsed or refractory NPM1-mutated AML who have no satisfactory alternative treatment options. Market Dynamics:
• Initial U.S. market opportunity for the approved indication is estimated at $350.0 million to $400.0 million annually.
• Added to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a Category 2A recommended treatment option for adults with relapsed or refractory NPM1-mutated AML (November 25, 2025).
• Market access decisions have enabled availability to covered lives in the U.S. within 90 days of approval, with at least 80% of private payors establishing coverage policies aligned with the label. Some private payors require patients to step through KOMZIFTI first before other menin inhibitors.

Ziftomenib - Development Programs (beyond approved monotherapy)

Financial Performance:

• Ziftomenib-related R&D costs: $142.579 million (+79.7% YoY from $79.338 million in 2024).
• Key Growth Drivers: Potential to address up to 50% of AML cases, including NPM1-mutated and KMT2A-rearranged AML, as well as other genetic subtypes dependent on the menin pathway. Total annual U.S. market opportunity across relapsed or refractory and frontline AML is estimated at approximately $7.0 billion. Product Portfolio:
• Newly Diagnosed AML:
  • KOMET-017-NIC (Phase 3): Evaluating ziftomenib with venetoclax plus azacitidine in newly diagnosed NPM1-mutated AML patients unfit for intensive chemotherapy. Dual-primary endpoints are CR and OS. Preliminary Phase 1b data (KOMET-007) showed high rates of durable morphologic complete responses (CRc 86%; CR 73%) and 68% molecular measurable residual disease (MRD) negativity.
  • KOMET-017-IC (Phase 3): Evaluating ziftomenib with induction chemotherapy (7+3) in newly diagnosed NPM1-mutated or KMT2A-rearranged AML. Dual-primary endpoints are MRD-negative CR and event-free survival (EFS). Topline results for the MRD-negative CR accelerated endpoint are anticipated in 2028.
  • KOMET-007 (cohort): Evaluating ziftomenib with 7+3 plus quizartinib in newly diagnosed NPM1/FLT3-ITD co-mutated AML.
• Relapsed or Refractory AML (combinations):
  • KOMET-007 (Phase 1): Evaluating ziftomenib with venetoclax and azacitidine in NPM1-mutated or KMT2A-rearranged AML. Objective response rate (ORR) was 65% and CRc rate was 48% in NPM1-mutated AML (n=51). ORR was 41% and CRc rate was 28% in KMT2A-rearranged AML (n=32).
  • KOMET-008 (Phase 1): Evaluating ziftomenib with gilteritinib in NPM1 and FLT3 co-mutated AML.
  • KOMET-008 (Phase 1): Evaluating ziftomenib with FLAG-IDA or low-dose cytarabine (LDAC) in NPM1-mutated or KMT2A-rearranged AML.
• Other Indications:
  • Gastrointestinal Stromal Tumors (GIST): Phase 1 KOMET-015 trial evaluating ziftomenib in combination with imatinib in advanced GIST after imatinib failure. Preclinical data showed robust and durable antitumor activity.
  • Pediatric Acute Leukemias: Clinical collaboration with Blood Cancer United (BCU) and Princess Máxima Center for Pediatric Oncology for a Phase 1 trial in KMT2A-rearranged, NUP98-rearranged or NPM1-mutated acute leukemia.
  • Maintenance Therapy: Supporting an investigator-sponsored trial (and may initiate company-sponsored) evaluating ziftomenib as maintenance therapy post-Hematopoietic Stem Cell Transplantation (HSCT) in NPM1-mutated or KMT2A-rearranged AML.

Next-Generation Menin Inhibitors

Product Portfolio:

• KO-7246: A next-generation menin inhibitor, expected to advance into IND-enabling studies in diabetes and cardiometabolic disorders in 2026. Preclinical data supports potential therapeutic utility in diabetes by restoring beta-cell mass.
• Additional Next-Generation Menin Inhibitors: Preclinical development for use in combination therapy for solid tumors in 2026.

Farnesyl Transferase Inhibitor Development Program

Financial Performance:

• Darlifarnib-related R&D costs: $26.714 million (+41.9% YoY from $18.829 million in 2024).
• Tipifarnib-related R&D costs: $3.490 million (-26.8% YoY from $4.770 million in 2024). Product Portfolio:
• Darlifarnib (Next-Generation FTI):
  • FIT-001 (Phase 1): First-in-human trial. Monotherapy in RAS-altered advanced solid tumors demonstrated manageable safety and encouraging antitumor activity in HRAS-mutated solid tumors.
  • Combination with Cabozantinib in RCC: Preliminary Phase 1a dose-escalation data showed manageable safety and antitumor activity (ORR 33-50% in ccRCC, 17-50% in patients with prior cabozantinib exposure). Phase 1b dose expansion initiated in February 2026.
  • Combination with Adagrasib in NSCLC, CRC, and PDAC: Evaluating in KRAS G12C-mutated solid tumors under a clinical collaboration with Mirati Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb). Preliminary clinical data from dose escalation anticipated in the first half of 2026.
• Tipifarnib (First-Generation FTI):
  • KURRENT-HN (Phase 1/2): Completed in Q3 2025. Combination with alpelisib (a PI3K alpha inhibitor from Novartis Pharma AG) in HNSCC with HRAS overexpression and/or PIK3CA mutation/amplification demonstrated a manageable safety profile and robust antitumor activity (ORR of 47% at a daily dose of tipifarnib 1200 mg with alpelisib 250 mg). Market Dynamics: Focus on developing FTIs in combination with other targeted therapies in large solid tumor indications (RCC, NSCLC, CRC, PDAC) to enhance antitumor activity, prevent/delay resistance, and improve therapeutic outcomes.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not mentioned in the filing.
• Dividend Payments: Kura Oncology, Inc. has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future. Dividend payments are currently prohibited by the terms of its term loan facility.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No specific future capital return commitments were disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $149.099 million
• Total Debt: $10.0 million (principal obligation under term loan facility)
• Net Cash Position: $657.2 million (Cash, cash equivalents and short-term investments of $667.2 million minus total debt of $10.0 million)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The Term Loans have a maturity date of November 2, 2027. Repayment is interest-only through May 1, 2027, followed by monthly payments of principal and accrued interest until maturity. The interest rate was 9.15% as of December 31, 2025.

Cash Flow Generation (Year Ended December 31, 2025):

• Operating Cash Flow: $(64.058) million (Net cash used in operating activities)
• Free Cash Flow: $(70.696) million (Operating Cash Flow of $(64.058) million minus Capital Expenditures of $6.638 million)
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Kura Oncology, Inc. does not own or operate manufacturing facilities. It relies entirely on third parties for the manufacture of its product candidates for preclinical and clinical testing, as well as for the commercial supply of KOMZIFTI and any other approved products. All product candidates are small molecules manufactured through synthetic processes.

Supply Chain Architecture:

• Key Suppliers & Partners: Relies on third-party contract manufacturers for active pharmaceutical ingredient (API) and drug product services, packaging, freight, raw material, and component suppliers. Some manufacturers and suppliers are located in China.
• Manufacturing Partners: Identifies and qualifies manufacturers for API and drug product services prior to NDA submission.
• Technology Partners: Relies on third-party collaborators for the development, validation, and regulatory approval of companion diagnostic tests.

Facility Network:

• Manufacturing: No owned manufacturing facilities; relies on third-party contract manufacturing facilities.
• Research & Development: Occupies approximately 32,512 square feet of office and lab space for its corporate headquarters in San Diego, California, and approximately 16,541 square feet of office space in Boston, Massachusetts.
• Distribution: Utilizes a select network of specialty distributors and specialty pharmacies to distribute KOMZIFTI in the United States.

Operational Metrics: Specific operational metrics such as capacity utilization, efficiency measures, or quality indicators were not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy:

• Direct Sales: Kura Oncology, Inc. has an experienced field sales team with an average of over 20 years of industry experience and deep hematology expertise. This team, along with Kyowa Kirin, collectively targets over 4,000 academic and community accounts in the U.S.
• Channel Partners:
  • Kyowa Kirin, Inc.: Co-promotes KOMZIFTI and other ziftomenib products in the U.S. under the Kyowa Co-Promotion Agreement. Kyowa Kirin Co., Ltd. is responsible for commercial strategy and commercialization of ziftomenib outside the U.S.
  • Specialty Distributors & Pharmacies: Utilizes a select network for optimized access, provider satisfaction, and prescription management in the U.S.
• Digital Platforms: The KURA RxKONNECT™ program offers tailored support for patients, including assistance with prior authorization, insurance education, appeals, and financial assistance.

Customer Portfolio:

• Enterprise Customers: Focuses on engaging with major academic and community institutions that treat AML patients.
• Strategic Partnerships: Key partnerships include Kyowa Kirin Co., Ltd. and Kyowa Kirin, Inc. (ziftomenib), Mirati Therapeutics, Inc. (for darlifarnib trials), Novartis Pharma AG (for tipifarnib trials), and Blood Cancer United and Princess Máxima Center for Pediatric Oncology (for pediatric ziftomenib trials).
• Customer Concentration: Not explicitly quantified, but the initial market for KOMZIFTI is a specific, smaller patient population.

Geographic Revenue Distribution:

• United States: Product revenue from KOMZIFTI sales is generated in the U.S.
• Growth Markets: Kyowa Kirin Co., Ltd. is responsible for commercializing ziftomenib outside the United States, indicating international market potential.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The development and commercialization of new oncology products is intensely competitive and characterized by rapid and significant technological change. Kura Oncology, Inc. operates in the rapidly evolving area of targeted therapeutics for genetically defined cancers. Industry Trends: There is a trend towards comprehensive molecular and genomic profiling and companion diagnostics to identify patient subsets most likely to benefit from targeted therapies. Market Size: The initial U.S. market for relapsed or refractory NPM1-mutated AML is estimated at $350.0 million to $400.0 million annually. The total annual U.S. market opportunity across relapsed or refractory and frontline AML is estimated at approximately $7.0 billion.

Competitive Positioning Matrix

Direct Competitors

Primary Competitors:

• Menin Inhibitors: Syndax (revumenib, FDA-approved), Janssen (Johnson & Johnson), Dainippon Sumitomo, Servier, Biomea Fusion, and CHARM Therapeutics.
• AML Therapies: Abbvie’s/Genentech’s venetoclax (VENCLEXTA®), Novartis’s midostaurin (RYDAPT®), Astellas’s gilteritinib (XOSPATA®), Bristol Myers Squibb’s enasidenib (IDHIFA®) and oral azacitidine (ONUREG®), Servier’s ivosidenib (TIBSOVO®), Rigel’s olutasidenib (REZLIDHIA®), and Daiichi-Sankyo’s quizartinib (VANFLYTA®).
• RCC Therapies (relevant for darlifarnib): Merck’s pembrolizumab (KEYTRUDA®), Bristol Myers Squibb’s nivolumab (OPDIVO®) and ipilimumab (YERVOY®), Exelixis’s cabozantinib (CABOMEYX®), Merck’s axitinib (INLYTA®), and Eisai’s lenvatinib (LENVIMA®).
• KRAS G12C-mutated Solid Tumor Therapies (relevant for darlifarnib): Amgen’s sotorasib (LUMAKRAS®) and Mirati Therapeutics, Inc.’s/Bristol Myers Squibb’s adagrasib (KRAZATI®). Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions are continuously emerging in the biopharmaceutical industry. Competitive Response Strategy: Kura Oncology, Inc.'s strategy involves discovering, acquiring, developing, and commercializing innovative agents, particularly in combination with existing standards of care, to deepen clinical responses and extend durability of benefit. The company emphasizes identifying molecular, genetic, or tumor-related characteristics for patient selection and building a sustainable product pipeline through internal R&D and strategic partnerships.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: The market opportunities for KOMZIFTI may be smaller than anticipated, and initial sales could deplete the prevalence pool of patients more quickly than expected. Competition from existing and future therapies that are superior, more effective, or less costly could adversely affect commercial viability.
• Technology Disruption: The focus on genetically defined cancers is a rapidly evolving area, and the company's approach may not lead to new marketable products or approved indications.
• Customer Concentration: The patient populations for targeted therapies are substantially smaller, and successful identification and reach of appropriate patients are critical.

Operational & Execution Risks

• Supply Chain Vulnerabilities: High reliance on third-party contractors for manufacturing product candidates and commercial supplies of KOMZIFTI, including some suppliers in China. Risks include production difficulties, quality control issues, and supply disruptions due to manufacturing problems, geopolitical events, or public health epidemics.
• Geographic Concentration: While operations are U.S.-based, global clinical trials and supply chain expose the company to international risks.
• Capacity Constraints: Dependence on third-party manufacturers introduces risks related to their ability to meet demand and comply with cGMP regulations.

Financial & Regulatory Risks

• Market & Financial Risks: Kura Oncology, Inc. has incurred losses since inception and expects to continue incurring significant operating losses. The ability to generate substantial product revenues and achieve profitability is unproven. The company will require substantial additional funding, which may not be available on reasonable terms or at all, potentially leading to dilution or restrictions on operations.
• Credit & Liquidity: Maintains cash balances at third-party financial institutions in excess of FDIC limits, posing a risk in case of bank failures or financial market instability.
• Regulatory & Compliance Risks:
  • FDA Approval & Post-Approval: Risk of failure to maintain FDA approval for KOMZIFTI or obtain approvals for additional indications. KOMZIFTI is subject to post-approval requirements and commitments (e.g., pediatric trials, long-term safety, companion diagnostic study), with non-compliance potentially leading to penalties or market withdrawal.
  • Companion Diagnostics: Failure by Kura Oncology, Inc. or its third-party collaborators to develop, validate, and obtain regulatory approval for diagnostic testing platforms could harm drug development and commercialization.
  • Healthcare Regulations: Subject to extensive fraud and abuse laws (Anti-Kickback Statute, False Claims Act), transparency laws (Physician Payments Sunshine Act), and privacy laws (HIPAA, GDPR, CCPA). Non-compliance could lead to significant penalties.
  • Healthcare Reform: Ongoing legislative and regulatory proposals in the U.S. and abroad (e.g., ACA, OBBBA, Medicare Drug Price Negotiation Program) could increase costs, restrict sales, and affect pricing and reimbursement.

Geopolitical & External Risks

• Geographic Dependencies: Reliance on manufacturers and suppliers in countries like China exposes the company to international trade policies and geopolitical tensions.
• Trade Relations: International trade policies, including tariffs, sanctions, and trade barriers, may increase R&D expenses, disrupt supply chains, and limit the ability to work with partners.
• Sanctions & Export Controls: Subject to U.S. and foreign export/import controls, sanctions, and anti-corruption laws, with potential for criminal liability and business limitations for violations. A Russian decree allows exploitation of inventions without consent or compensation, potentially impacting IP rights in Russia.

Innovation & Technology Leadership

Research & Development Focus: Kura Oncology, Inc.'s R&D is centered on precision medicines for cancer, leveraging advancements in cancer genetics and molecular diagnostic tools. The company employs a translational research approach, synthesizing basic research, preclinical, and clinical data to guide its precision medicine strategy. Core Technology Areas:

• Menin Inhibition: Developing ziftomenib (KOMZIFTI) and next-generation menin inhibitors (e.g., KO-7246) to target KMT2A gene rearrangements and NPM1 mutations in acute leukemias, and exploring applications in GIST, diabetes, and cardiometabolic disorders.
• Farnesyl Transferase Inhibition (FTI): Developing darlifarnib (next-generation FTI) and has evaluated tipifarnib (first-generation FTI) to address mechanisms of adaptive and innate resistance in solid tumors, often in combination with other targeted therapies. Innovation Pipeline:
• Ziftomenib: Expanding into frontline AML (intensive and non-intensive chemotherapy combinations), pediatric acute leukemias, and maintenance therapy post-HSCT. Also exploring GIST.
• Next-Generation Menin Inhibitors: KO-7246 for diabetes and cardiometabolic diseases, and other candidates for solid tumors.
• Darlifarnib: Combinations with cabozantinib in RCC and adagrasib in KRAS G12C-mutated NSCLC, CRC, and PDAC. Plans to explore novel PI3K alpha and RAS inhibitors as combination partners.

Intellectual Property Portfolio:

• Patent Strategy: Seeks to protect its proprietary position through licensing and filing U.S., international, and foreign patent applications covering composition-of-matter, biomarkers, formulations, processes, and methods of use.
• Patent Holdings:
  • Ziftomenib: Exclusively licensed from the University of Michigan, with issued U.S. and foreign patents covering composition of matter and methods of use. Eight U.S. patents for KOMZIFTI are listed in the Orange Book, with base expiration dates extending to July 16, 2044.
  • Darlifarnib: Owns several patent families, including two granted composition-of-matter patents and numerous worldwide pending applications.
• Licensing Programs: Key in-license agreement with the University of Michigan for its menin-KMT2A program. Out-license agreement with Kyowa Kirin Co., Ltd. for global rights to ziftomenib.
• IP Litigation: The company may become involved in lawsuits to protect or enforce its patents or defend against infringement claims, which can be expensive and time-consuming.

Technology Partnerships: Engages in clinical collaborations with companies like Mirati Therapeutics, Inc. (for adagrasib) and Novartis Pharma AG (for alpelisib) for combination trials. Also collaborates with academic and research institutions (e.g., Blood Cancer United, Princess Máxima Center for Pediatric Oncology) for clinical development.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Kura Oncology, Inc.'s future success is highly dependent on the expertise of its Chief Executive Officer and other principal members of its management, scientific, clinical, and commercial teams. The company emphasizes the ability to attract, retain, and motivate qualified personnel. Board Composition: The board of directors addresses cybersecurity risk management as part of its general oversight function, with the audit committee specifically responsible for overseeing these processes. The board is divided into three classes.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: 260 full-time employees.
• Geographic Distribution: All employees are based in the United States.
• Skill Mix: 50% of employees are in research, development, and supply chain functions, while 50% are in selling, general, and administrative capacities.

Talent Management:

• Acquisition & Retention: Kura Oncology, Inc. invests in its employees through high-quality benefits, various health and wellness initiatives, competitive compensation packages, and fair compensation practices.
• Retention Metrics: Not explicitly disclosed.
• Employee Value Proposition: The company's Code of Business Conduct and Ethics emphasizes core values of respect, integrity, collaboration, innovation, trust, and excellence, aiming to foster a culture of honesty and accountability.

Diversity & Development:

• Diversity Metrics: Not explicitly disclosed.
• Development Programs: The company works with individual business functions to provide training and hands-on support for managers and leaders, assessing talent and identifying development opportunities.
• Culture & Engagement: A comprehensive training program on the Code of Business Conduct and Ethics is provided annually to all staff and management employees.

Environmental & Social Impact

Environmental Commitments: Kura Oncology, Inc. is subject to environmental, health, and safety laws and regulations, particularly those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. The company generally contracts with third parties for waste disposal and does not currently expect these regulations to materially impact its present or planned future activities. Supply Chain Sustainability: Not explicitly disclosed in the filing. Social Impact Initiatives: Not explicitly disclosed in the filing.

Business Cyclicality & Seasonality

Demand Patterns: The filing does not explicitly discuss seasonal trends or demand patterns for its products or product candidates. Economic Sensitivity: Kura Oncology, Inc.'s results of operations could be adversely affected by general conditions in the global economy and financial markets, including volatility and uncertainty stemming from global pandemics, bank failures, changes in interest rates, tariffs, and economic inflation. Industry Cycles: Not explicitly discussed in the context of specific industry cycles.

Planning & Forecasting: Not explicitly disclosed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Kura Oncology, Inc. is subject to extensive regulation by the FDA in the United States and comparable regulatory authorities in other countries (e.g., European Medicines Agency, Japan’s Pharmaceuticals and Medical Devices Agency). This includes regulations governing research, development, testing, manufacture (cGMP), clinical trials (GCP), approval, labeling, promotion, distribution, and post-approval monitoring. Industry-Specific Regulations:

• Expedited Programs: Ziftomenib previously received Breakthrough Therapy, Fast Track, and Orphan Drug Designations, as well as Priority Review from the FDA.
• Project Optimus: The FDA's Project Optimus initiative emphasizes dose optimization and selection in oncology drug development, potentially requiring additional trials pre- or post-approval.
• Post-Approval Requirements: KOMZIFTI's approval is subject to post-marketing requirements and commitments, including pediatric trials, long-term safety studies, pharmacokinetic evaluations, and a study to support an NPM1 mutation companion diagnostic.
• Companion Diagnostics: In vitro companion diagnostics are regulated as medical devices and require separate clearance or approval (e.g., PMA) by the FDA, often concurrently with the therapeutic product. International Compliance: Marketing and sales in foreign jurisdictions require separate marketing approvals and compliance with varying regulatory requirements, including data privacy laws like the General Data Protection Regulation (GDPR) in Europe, which imposes strict requirements and significant fines for non-compliance. Trade & Export Controls: The company is subject to U.S. and foreign export and import controls, sanctions (e.g., OFAC), embargoes, and anti-corruption laws (e.g., Foreign Corrupt Practices Act). Violations can lead to substantial penalties. Legal Proceedings: Kura Oncology, Inc. is not currently a party to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: For the year ended December 31, 2025, the effective income tax rate differed from the statutory federal rate of 21% primarily due to state income taxes, research and development tax credits, orphan drug credits, changes in valuation allowance, changes in unrecognized tax benefits, and share-based compensation.
• Geographic Tax Planning: Not explicitly detailed in the filing.
• Tax Reform Impact: Recent legislation, including the One Big Beautiful Bill Act (OBBBA) in 2025, the Inflation Reduction Act (IRA) in 2022, and the Tax Cuts and Jobs Act in 2017, has made significant changes to U.S. tax laws. The OBBBA restored deductibility of domestic R&E expenditures for tax years beginning after December 31, 2024, but retained capitalization for foreign R&E. NOLs and Tax Credits:
• As of December 31, 2025, Kura Oncology, Inc. had federal net operating loss (NOL) carryforwards of $310.5 million (indefinite carryforward, limited to 80% of taxable income) and state NOL carryforwards of $667.6 million (expiring starting 2034).
• Federal research and development credit carryforwards were $82.1 million (expiring starting 2040), and state credits were $12.0 million (some indefinite, some expiring starting 2030).
• A full valuation allowance of $363.890 million was recorded against deferred tax assets as of December 31, 2025, due to the uncertainty of realization.
• An ownership change occurred in 2015, but the annual utilization limitation was deemed sufficient. Unrecognized Tax Benefits: As of December 31, 2025, gross unrecognized tax benefits totaled $25.721 million. No significant change is expected in the next 12 months. Income Taxes Paid (2025): Federal income taxes paid were $1.8 million, with state taxes paid in Pennsylvania ($0.18 million), Illinois ($0.206 million), and other states ($0.122 million).

Insurance & Risk Transfer

Risk Management Framework: Kura Oncology, Inc. maintains product liability and clinical trial liability insurance coverage. It also holds a pollution liability policy. However, the company does not maintain insurance for environmental liability or toxic tort claims that may be asserted in connection with its storage or disposal of biological, hazardous, or radioactive materials. Risk Transfer Mechanisms: Not explicitly detailed beyond insurance coverage.